Bristol Myers Squibb
Last updated Jun 20, 2026
Evidence Sources
7
Competitive Findings
3
Portfolio Developments
1
Regulatory Precedents
8
Clinical Programs
3
Confidence Coverage
71%
Audit
- Competitor findings: 3
- Portfolio developments: 1
- Self-competition findings removed: 1
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- Multiple Myeloma
- Immune Checkpoint Inhibitor
- Immunotherapy
- Monoclonal Antibodies
Highest priority development: Phase 3 Study of BLU-5937 Shows Promise for Refractory Chronic Cough
Portfolio development
Phase 3 Study of BLU-5937 Shows Promise for Refractory Chronic Cough is an owned Bristol Myers Squibb portfolio development in Respiratory · Chronic Cough.
Competitive pressure: Moderate
Portfolio impact: High
Evidence coverage: 71%
Active Signals
12
Investigate Priority
3
Opportunity Score
721
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- InvestigateJun 20, 2026Score 66RBMS1 identified as a key factor in multiple myeloma malignancy and macrophage polarization
Oncology · Multiple Myeloma
- InvestigateJun 17, 2026Score 66Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma
Oncology · Melanoma
- MonitorJun 20, 2026Score 64FDA Accepts Supplement Application for YERVOY (ipilimumab)
Oncology · Immune Checkpoint Inhibitor
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
- Phase 3 Study of BLU-5937 Shows Promise for Refractory Chronic CoughLow Confidence · 0%
Phase III success
Sources (3)Bristol Myers SquibbClinicalTrials.govPortfolio
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
- SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025Moderate Confidence · 63%
Potential competitive pressure
Sources (2)Bristol Myers SquibbCompetitiva - Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic AdenocarcinomaHigh Confidence · 88%
Limited competitive pressure indicated
Sources (2)Humanexa SignalsCompetitiva - Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic AdenocarcinomaModerate Confidence · 81%
Limited competitive pressure indicated
Sources (2)ClinicalTrials.govCompetitiva
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — HERCEPTIN HYLECTA (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — SANDIMMUNE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Investigational New Drug (IND) ApplicationModerate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — YERVOY (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025Moderate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov - Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic AdenocarcinomaModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov - Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic AdenocarcinomaModerate Confidence · 68%
Competitive clinical program activity indicated
Sources (2)CompetitivaClinicalTrials.gov
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- InvestigateScore 66RBMS1 identified as a key factor in multiple myeloma malignancy and macrophage polarization
Oncology · Multiple Myeloma
- InvestigateScore 66Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma
Oncology · Melanoma
- InvestigateScore 60Polyploid Giant Cancer Cells Drive Aggressiveness in Ovarian Cancer and Indicate Poor Prognosis
Oncology · Ovarian Cancer
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Bristol Myers Squibb right now?
- Which regulatory precedents should Bristol Myers Squibb monitor in Oncology and Multiple Myeloma?
- How does Keytruda compare to the nearest competitive programs?
- What signals require immediate investigation for Bristol Myers Squibb?
- Summarize the strategic implications of recent developments for Bristol Myers Squibb.
- Where is the greatest uncertainty in Bristol Myers Squibb's competitive positioning?